eTheRNA immunotherapies is driving mRNA technology and therapeutic product development to deliver an innovative generation of RNA chemistries, RNA process technologies and a new and advanced generation of therapeutic and vaccine products. eTheRNA uses its established R&D foundations and in-house GMP manufacturing facilities and builds on its proprietary mRNA, mRNA adjuvant and mRNA formulation platforms to progress technology innovation and product development. eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.